Bullish option flow detected in Crispr Therapeutics with 4,198 calls trading, 1.1x expected, and implied vol increasing almost 3 points to 57.07%. Jan-24 63 puts and 1/12 weekly 65 calls are the most active options, with total volume in those strikes near 1,000 contracts. The Put/Call Ratio is 0.47. Earnings are expected on February 20th.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRSP:
- Baird finds ‘incremental negative’ in Crispr’s 2024 outlook
- Crispr Therapeutics announces 2024 outlook
- Crispr Therapeutics put volume heavy and directionally bearish
- William Blair biotech analysts to hold an analyst/industry conference call
- The biopharmaceuticals stocks to own in 2024, according to BofA